2.50Open2.50Pre Close0 Volume8 Open Interest25.00Strike Price0.00Turnover99.24%IV8.14%PremiumDec 20, 2024Expiry Date0.43Intrinsic Value100Multiplier20DDays to Expiry2.07Extrinsic Value100Contract SizeAmericanOptions Type0.5791Delta0.0664Gamma9.88Leverage Ratio-0.0601Theta0.0066Rho5.72Eff Leverage0.0232Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet